Search Results | Clinical Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

S R Alberts, C Erlichman, J M Reid, J A Sloan, M M Ames, R L Richardson, R M Goldberg

Clin Cancer Res (1998) 4 (9): 2111–2117.

Published: 01 September 1998

View article

Journal Articles

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

A A Adjei, M Charron, E K Rowinsky, P A Svingen, J Miller, J M Reid, J Sebolt-Leopold, M M Ames, S H Kaufmann

Clin Cancer Res (1998) 4 (3): 683–691.

Published: 01 March 1998

View article

Journal Articles

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

I I Budihardjo, D L Walker, P A Svingen, C A Buckwalter, S Desnoyers, S Eckdahl, G M Shah, G G Poirier, J M Reid, M M Ames, S H Kaufmann

Clin Cancer Res (1998) 4 (1): 117–130.

Published: 01 January 1998

View article

Journal Articles

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

R M Goldberg, J M Reid, M M Ames, J A Sloan, J Rubin, C Erlichman, M J Kuffel, T R Fitch

Clin Cancer Res (1997) 3 (12): 2363–2370.

Published: 01 December 1997

View article

Journal Articles

Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.

J M Reid, D C Stevens, J Rubin, M M Ames

Clin Cancer Res (1997) 3 (12): 2393–2398.

Published: 01 December 1997

View article

Journal Articles

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

J B Lawrence, C A Conover, T C Haddad, J N Ingle, J M Reid, M M Ames, V J Suman, R S Marks, C Erlichman, L C Hartmann

Clin Cancer Res (1997) 3 (10): 1713–1720.

Published: 01 October 1997

View article

Journal Articles

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

M Dhodapkar, J Rubin, J M Reid, P A Burch, H C Pitot, J C Buckner, M M Ames, V J Suman

Clin Cancer Res (1997) 3 (7): 1093–1100.

Published: 01 July 1997

View article

NARROW

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

Email alerts

AACR Journals

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only